Clinical trial
Effect of rHDL on Atherosclerosis - Safety and Efficacy: THE ERASE TRIAL
NCT00225719 · CSL Limited, Industry · Completed
Key facts
| NCT number | NCT00225719 |
|---|---|
| Title | Effect of rHDL on Atherosclerosis - Safety and Efficacy: THE ERASE TRIAL |
| Official title | Regression of Coronary Atherosclerotic Lesions After rHDL Infusions in Acute Coronary Syndrome Patients as Assessed by Intravascular Ultrasound. |
| Lead sponsor | CSL Limited, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Acute Coronary Syndromes |
| Intervention type | Drug |
| Interventions | rHDL |
| Enrollment | 180 |
| Start date | Jul 1, 2005 |
| First posted | Sep 26, 2005 |
| Last update posted | Nov 10, 2008 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: